Meet PSI at Advances in IBD 2026!
PSI CRO is attending Advances in IBD 2026 to discuss the operational strategies sponsors are using to maintain enrollment predictability and endpoint integrity in complex pivotal IBD studies.
Sponsors evaluating Crohn’s disease and ulcerative colitis programs can meet with PSI to discuss enrollment planning, site selection strategy, placebo response mitigation, and operational execution across global GI trials.
PSI supports 35% of all industry-sponsored ulcerative colitis trials and enrolls patients more than 50% faster in GI indications versus industry benchmarks, supported by a network of 6,000 GI sites across 60 countries.
Attending team members:
- Scott Clark
Senior Director, Business Development - Nirmal Kaur
Medical Monitor, Medical Affairs
Related resources:
White paper: Placebo response in IBD trials – PSI CRO
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
Blog: Advances in IBD treatment considerations, GI trial design, and the impact of AI
Case Study: Managing enrollment and site performance in competitive upper GI trial programs
